Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Direkt zur Navigaton springen.
Direkt zum Inhalt springen.

Navigation/Suche

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

James, S; Christoffersen, AD; David, JP; Hacker, M; Jensen, MDRJ; Mellbin, L; Pieber, TR; Ripa, RS; Rossing, P; Svehlikova, E; Kjaer, A.
Effect of Once-Weekly Subcutaneous Semaglutide on Arterial Inflammation in People with Type 2 Diabetes and Cardiovascular Disease Using PET-MRI: Primary Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Am Heart J. 2025; Doi: 10.1016/j.ahj.2025.05.001
PubMed FullText FullText_MUG

Co-Autor*innen der Med Uni Graz: Pieber Thomas; Svehlikova Eva
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Semaglutide has demonstrated cardiovascular benefits in people with type 2 diabetes (T2D) with cardiovascular disease (CVD). Inflammation plays a well-documented role in atherosclerosis and glucagon-like peptide-1 receptor agonists, like semaglutide, have shown anti-inflammatory effects in animal and clinical studies. This trial investigated the effect of semaglutide on atherosclerotic inflammation in the carotid arteries using positron emission tomography (PET)-magnetic resonance imaging (MRI). METHODS: Patients with T2D and CVD were randomized to double-blinded once-weekly subcutaneous semaglutide 1.0 mg or placebo. The primary and key secondary endpoints used PET-MRI with [¹⁸F]FDG and [⁶⁸Ga]DOTATATE tracers to assess change from baseline to week 26 in plaque inflammation in the segments of the carotid arteries that were determined to be the most diseased and where plaque inflammation was quantified by the maximum target-to-background ratio (TBR_max) of the tracers. Additional secondary endpoints assessed plaque morphology and burden using MRI at week 52, including total wall volume, lipid-rich necrotic core volume, and fibrous cap thickness. RESULTS: Of 101 patients, 87.1% were male, mean age was 66 years and they were well-treated according to guidelines. No significant treatment differences were observed between semaglutide and placebo for change in plaque inflammation at week 26 with either tracer; TBR_max of FDG (estimated treatment difference [ETD]: 0.033, 95% confidence interval [CI]: -0.118;0.184) and [⁶⁸Ga]DOTATATE (ETD: 0.045, 95% CI: -‍0.314;0.404). CONCLUSIONS: This trial explored the feasibility of following plaque inflammation with PET-MRI using [¹⁸F]FDG and [⁶⁸Ga]DOTATATE. A significant effect of semaglutide versus placebo on carotid plaque inflammation could not be detected through the methodology used in this trial, likely due to minimal baseline inflammation. However, this does not exclude an effect of semaglutide on inflammation seen in previous preclinical and clinical studies. TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04032197.